Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 16/20 | 0.57 |
| ▸ | EGFR | P00533 | 14/20 | 0.55 |
| ▸ | ITK | Q08881 | 4/20 | 0.55 |
| ▸ | JAK2 | O60674 | 1/20 | 0.55 |
| ▸ | LYN | P07948 | 1/20 | 0.55 |
| ▸ | TEC | P42680 | 1/20 | 0.55 |
| ▸ | TXK | P42681 | 1/20 | 0.55 |
| ▸ | BMX | P51813 | 1/20 | 0.55 |
| ▸ | JAK3 | P52333 | 1/20 | 0.55 |
| ▸ | CD69 | Q07108 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17388664 | 0.78 | BTK (0.64) | BTKEGFRITKJAK2LYN | |
| SCHEMBL29847707 | 0.78 | EGFR (0.85) | BTKEGFRITKJAK2LYN | |
| SCHEMBL16514391 | 0.78 | EGFR (0.85) | BTKEGFRITKJAK2LYN | |
| SCHEMBL15987165 | 0.77 | EGFR (0.65) | BTKEGFRITKJAK2LYN | |
| SCHEMBL17388689 | 0.77 | CDK4 (0.45) | BTKEGFRITKJAK2LYN | |
| SCHEMBL15987164 | 0.75 | BTK (0.59) | BTKEGFRITKJAK2LYN | |
| SCHEMBL26158821 | 0.73 | EGFR (0.82) | BTKEGFRITKJAK2LYN | |
| SCHEMBL24377868 | 0.73 | BTK (1.00) | BTKEGFRITKJAK2LYN | |
| SCHEMBL30379597 | 0.72 | JAK3 (0.43) | BTKITKJAK2JAK3 | |
| SCHEMBL25052136 | 0.72 | JAK3 (0.43) | BTKITKJAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708326-B2 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708326-B2 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708326-B2 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2017-07-18 | — | — | US | disclosed |
| US-20160002241-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, LLC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160002241-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, LLC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-20160002241-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, LLC. (US) | 2016-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002241-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, LCK | BTK 1/4885EGFR 785/4885ITK 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.